Exhibit 99.1 Zynex Reports First Quarter 2025 Financial Results ENGLEWOOD, Colo., April 29, 2025 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary "In the first quarter of 2025, we continued to see steady orders for our pain management a ...

Core Insights - Zynex, Inc. reported a net revenue of $26.6 million for Q1 2025, a decrease from $46.5 million in Q1 2024, primarily due to a temporary suspension of payments from its largest insurance customer, Tricare [4][6] - The company experienced a net loss of $10.4 million, or $0.33 per share, compared to a net income of $10,000 in the same quarter last year [6][18] - Zynex plans to submit its FDA application for the NiCO laser pulse oximeter soon, which is expected to drive new customer acquisition and diversify its product offerings [3] Management Commentary - The company noted a 3% year-over-year decrease in total orders, attributed to a 39% reduction in sales force headcount, but expressed optimism about the productivity of the remaining sales representatives [2] - Zynex is appealing the payment suspension from Tricare and expects a response by June 2025 [2] Financial Performance - Gross profit for Q1 2025 was $18.2 million, representing 69% of revenue, down from 80% in Q1 2024, impacted by the Tricare payment suspension [4] - Sales and marketing expenses decreased by 28% to $16.9 million, while general and administrative expenses rose to $14.4 million from $13.3 million year-over-year [5] Cash Flow and Guidance - Cash flows from operations for Q1 2025 were negative at $10.5 million, with cash and cash equivalents at $23.9 million as of March 31, 2025 [7] - The company anticipates Q2 2025 net revenue of at least $27 million and expects to improve loss per share to ($0.20) or better [8] Balance Sheet Highlights - As of March 31, 2025, Zynex had total assets of $105.8 million, down from $122.1 million at the end of 2024 [15][17] - Current liabilities were $16.3 million, with total liabilities amounting to $85 million [16][17]

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. for alleged securities fraud affecting investors between March 13, 2023, and March 11, 2025 [1] Group 1: Allegations - The lawsuit claims that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2] - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2] - The lawsuit suggests that Zynex may face adverse consequences such as removal from insurer networks and penalties from the federal government [2] - Defendants' positive statements regarding Zynex's business, operations, and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses in Zynex, Inc. during the relevant time frame have until May 19, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI). Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=145088&from=3 CLASS PERIOD: March 13, 2023 to Marc ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zynex, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from March 13, 2023, to March 11, 2025 [1] Group 1: Allegations Against Zynex, Inc. - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [1] - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1] - As a result of these practices, Zynex is likely to face adverse consequences, including removal from insurer networks and penalties from the federal government [1] - The positive statements made by the defendants about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased shares of ZYXI during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment [1] - The deadline for shareholders to register for the class action is May 19, 2025, and there is no cost or obligation to participate [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2] Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3] - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3] - The firm seeks recovery for investors who incurred losses due to false or misleading statements that led to artificial inflation of the company's stock [3]

PHILADELPHIA, April 24, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Zynex securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of the ...

NEW YORK, April 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI). Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ZYXI during the timeframe listed above, you will be enrolled ...

Core Viewpoint - Zynex, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its business practices, particularly related to inflated revenue and improper product shipments [3][4]. Summary by Sections Allegations - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [3] - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [3] - As a result of these practices, Zynex is likely to face adverse consequences, including removal from insurer networks and federal penalties [3] - Defendants' positive statements about the company's business and prospects were materially misleading and lacked a reasonable basis [3] Class Action Details - The class period for the lawsuit is from March 13, 2023, to March 11, 2025 [3] - Shareholders are encouraged to register for the class action by May 19, 2025, to potentially become lead plaintiffs [4] - There is no cost or obligation for shareholders to participate in the case [4] Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5]

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the “Class Period”), of the important May 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...

ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025.  Financial results will be issued in a press release prior to the call.Zynex management will host the co ...